secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001396814-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M
-----------------------------------------------------------------------

- Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.
- EXPAREL net product sales $130.4M, avg daily volumes up 6%, offset by 340B pricing; ZILRETTA $24.3M; iovera° $4.0M.
- Adjusted EBITDA $41.9M vs $53.8M in Q1 2022; non-GAAP net income $24.3M ($0.53 diluted share).
- FDA accepted sNDA for EXPAREL lower-extremity nerve blocks; PDUFA date Nov 13, 2023.
- Repaid $287.5M Term Loan B using $150M new Term Loan A and cash; appointed Christopher Young Chief Manufacturing Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/0001396814-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/pcrx-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer